Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | +0.89% | -10.32% | +105.45% |
Financials (USD)
Sales 2024 * | 7.5M | Sales 2025 * | 18.75M | Capitalization | 41.34M |
---|---|---|---|---|---|
Net income 2024 * | -67M | Net income 2025 * | -72M | EV / Sales 2024 * | -20.7 x |
Net cash position 2024 * | 196M | Net cash position 2025 * | 302M | EV / Sales 2025 * | -13.9 x |
P/E ratio 2024 * |
-0.68
x | P/E ratio 2025 * |
-0.92
x | Employees | 73 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.2% |
Latest transcript on Xilio Therapeutics, Inc.
1 day | +0.89% | ||
1 week | -10.32% | ||
Current month | +8.65% | ||
1 month | -10.32% | ||
3 months | +88.33% | ||
6 months | -13.74% | ||
Current year | +105.45% |
Managers | Title | Age | Since |
---|---|---|---|
René Russo
CEO | Chief Executive Officer | 49 | 19-05-21 |
Kevin Brennan
DFI | Director of Finance/CFO | 54 | - |
Chief Tech/Sci/R&D Officer | - | 22-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Clancy
CHM | Chairman | 62 | 20-07-22 |
Daniel Curran
BRD | Director/Board Member | 57 | 20-11-30 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 22-09-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-14 | 1.13 | +0.89% | 109 034 |
24-05-13 | 1.12 | -5.08% | 273,985 |
24-05-10 | 1.18 | -6.35% | 230,498 |
24-05-09 | 1.26 | +4.13% | 217,114 |
24-05-08 | 1.21 | -3.97% | 157,669 |
Delayed Quote Nasdaq, May 14, 2024 at 01:27 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+105.45% | 41.34M | |
+27.48% | 48.16B | |
-0.73% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+10.66% | 25.59B | |
-22.64% | 18.96B | |
+8.16% | 12.92B | |
+29.29% | 12.03B | |
-1.99% | 11.77B |
- Stock Market
- Equities
- XLO Stock